Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04631029 · ClinicalTrials.gov registry record · Phase 1
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
A Phase 1 study of Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 5
- Study locations
NCT04631029 is a Phase 1 study of Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3 participants, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04631029, a Phase 1 study of Malignant Solid Neoplasm and Metastatic Malignant Neoplasm in the Brain, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase I trial seeks to find out the best dose, possible benefits and/or side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer that has spread (extensive-stage small cell lung cancer). Entinostat and etoposide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Carboplatin is a chemotherapy drug that attaches to deoxyribonucleic acid (DNA) and may kill tumor cells. Giving entinostat in combination with atezolizumab, carboplatin and etoposide may work better than atezolizumab, carboplatin and etoposide alone.
Conditions Studied
Interventions
- DRUG Carboplatin
- BIOLOGICAL Atezolizumab
- DRUG Etoposide
- DRUG Entinostat
Study Locations (5)
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- University of Pittsburgh Cancer Institute (UPCI) - Pittsburgh
Utah
- Huntsman Cancer Institute/University of Utah - Salt Lake City
Virginia
- University of Virginia Cancer Center - Charlottesville
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-04-27 |
| Est. Completion | 2023-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04631029
The ClinicalTrials.gov registry entry for NCT04631029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,141-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (100% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT04631029 reports 5 study locations spanning 5 distinct geographic areas - top geographies include New York, Pennsylvania, Utah.
Frequently Asked Questions
What is clinical trial NCT04631029 about?
NCT04631029 is a clinical study titled "Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread". This phase I trial seeks to find out the best dose, possible benefits and/or side effects of entinostat in combination with atezolizumab, carboplatin and etoposide for the treatment of previously untreated aggressive lung cancer that has spread (extensive-stage small cell lung cancer). Entinostat an...
What is the current status of trial NCT04631029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-04-27. Estimated completion is 2023-07-11.
What conditions does trial NCT04631029 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain, Extensive Stage Lung Small Cell Carcinoma.
What interventions are being tested in trial NCT04631029?
The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (BIOLOGICAL), Etoposide (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT04631029?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04631029 being conducted?
This trial has 5 study locations across New York, Pennsylvania, Utah, Virginia, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
-
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
RECRUITING · Phase 1
Explore more on PlainTrial
Malignant Solid Neoplasm
All registered trials for this condition
Metastatic Malignant Neoplasm in the Brain
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.